← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neuroinfla (TREM2) — 0.00 Kinetic Threshold Model Predicts CHIP-Mediated Clearance Req (STUB1) — 0.00 NAD+-Dependent Upregulation of MCT1 Expression to Restore Ne (SLC16A1 (MCT1)) — 0.00 LXRα-Selective Agonism to Enhance Hepatic APOE Secretion and (LXRα (NR1H3)) — 0.00 Enhancement of Astrocytic Ketone Body Production via HMGCS2 (HMGCS2) — 0.00 CD38 Inhibition to Preserve NAD+ Pools and Prevent PARP1-Med (CD38, PARP1, SIRT1/3) — 0.00 FUS-Enhanced AAV-PHP.eB Delivery for Microglial IGFBPL1 Expr (IGFBPL1) — 0.00 CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL (CCR2, TLR4, IL1B) — 0.00 LXRβ-Selective Agonism Enhances CYP2J2-Mediated DHA Epoxide (NR1H2 (LXRβ)) — 0.00 Rare TREM2-TYROBP pathway variants complement standard PRS b (PLCG2) — 0.00 Closed-loop transcranial focused ultrasound with adaptive AP (PVALB) — 0.00 Circulating hs-CRP as Disease-Modifying Target via Astrocyti (CRP → NLRP3 → IL-1β/IL-18) — 0.00 CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation (CXCL12) — 0.00 TBK1 Loss Drives Motor Neuron Death Through Impaired Mitopha (TBK1 → OPTN / p62 / FIP200 / mitophagy machinery) — 0.00 Dynamic Blood-Based Exosome Panel for Real-Time Neuroinflamm (CHI3L1/TREM2/NRGN) — 0.00 AD Polygenic Risk Score predicts transcriptomic aging accele (%s) — 0.00 Lentiviral-Mediated Astrocytic IGFBPL1 Expression via GFAP P (IGFBPL1) — 0.00 CSF TREM2 Fragment Ratio Integrated with Neuroinflammatory C (TREM2) — 0.00 Plasma TREM2 Ectodomain Glycosylation Patterns as Microglial (TREM2/ST6GAL1/MGAT5) — 0.00 SASP-Secreted MMP-9 from Senescent Microglia Disrupts TDP-43 (MMP9 → nuclear import machinery (KPNA1, NUP proteins, LMNA) → TARDBP cytoplasmic mislocalization) — 0.00 Astrocytic TREM2-Like Receptor Modulation of Synaptic Streng (TREML2) — 0.00 Mitochondrial Dysfunction-Mediated Neurodegeneration in Alzh (TFAM) — 0.00 TREM2-Mediated Microglial Regulation of Oligodendrocyte Prec (TREM2) — 0.00 Microglia-Mediated Synaptic Pruning Modulation to Optimize F (CX3CR1) — 0.00 TBK1 Loss Drives Microglial Senescence-SASP to Generate MMP- (TBK1) — 0.00 Ultrasound-Responsive Liposomal Nanocarriers with Thermosens (IGFBPL1) — 0.00 Optogenetic restoration of SST interneuron-mediated dendriti (SST) — 0.00 CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab (CCR2) — 0.00 CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab (CCR2) — 0.00 TREM2-Mediated Senescent Microglial Reprogramming of Astrocy (TREM2) — 0.00
Add
|
× S100B as Active Pathogeni
S100B · - · -
Composite 0.647
Price $0.53
Evidence For 0
Evidence Against 0
S100B operates as a pathogenic DAMP in the perivascular space, binding RAGE on brain endothelial cells to trigger NF-κB-mediated downregulation of claudin-5 and occludin, creating a self-amplifying BBB disruption loop. Longitudinal plasma S100B slope — not single timepoint — is the mechanistically meaningful metric.
Radar Chart — 10 Dimensions
Score Breakdown
Dimension S100B as Active Pathogenic BBB Mechanistic 0.750 Evidence 0.180 Novelty 0.780 Feasibility 0.720 Impact 0.000 Druggability 0.500 Safety 0.450 Competition 0.680 Data 0.750 Reproducible 0.700 KG Connect 0.500
Evidence S100B as Active Pathogenic BBB-Disrupting Signal via RAGE/NF No evidence citations yet
Price History Overlay